Larazotide
Clinical evidenceThe most advanced attempt yet to keep the gut lining tight — a promising idea that failed its final test.
What it is
Larazotide is a small synthetic peptide designed for celiac disease. Gluten can make the body loosen the junctions between intestinal cells, letting fragments through that trigger the immune attack. This drug aims to keep those junctions closed, even when a gluten-free diet is not perfect. It is taken by mouth and works locally in the gut.
How it works
A protein called zonulin acts as the signal that loosens the spaces between gut-lining cells. Larazotide blocks zonulin. By holding the barrier tight, it tries to blunt the leak that feeds the immune response, rather than treating the immune response itself.
What people report
- ✦Targeted the actual 'leaky gut' mechanism with a real drug candidate
- ✦Reduced symptoms in celiac patients in a phase 2b trial
- ✦Gave the whole field of intestinal permeability its most credible clinical shot
- ✦Works as an add-on for people who still have symptoms despite a gluten-free diet
Typical use
It was studied as an ongoing adjunct to a gluten-free diet, not as a short cycle. No product is available today.
Dosing reference
The phase 2b used 0.5 mg three times daily. No approved dose exists. Verify against the literature if reviewing for background.
Reference only — not a recommendation. Verify via primary sources.
Watch for
The pivotal phase 3 was stopped in 2022 after an interim analysis found it could not reach significance, and no further development has been announced. The mechanism remains interesting; the drug did not clear the bar.
Educational content — not medical advice.